Review study for adults with metastatic UC treated with specific drugs
Part of Cancer clinical trials.
This is a study that looks back at past medical records of adults with metastatic urinary tract cancer. It specifically includes people who received certain immunotherapy or antibody-drug treatments during set time periods, to help researchers understand outcomes and care patterns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18 years old.
- Your diagnosis is urinary tract cancer (UC) confirmed by biopsy/pathology results.
- Your cancer has spread to other parts of the body (metastatic disease), confirmed by imaging scans or biopsy.
- You received pembrolizumab at least once between Jan 1, 2018 and Nov 30, 2021, OR you received enfortumab vedotin at least once between Jun 1, 2022 and Jul 31, 2023.
- Your records must show you had the UC and metastatic disease confirmed; if not, you likely cannot be included.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry study collects information from people with different types of advanced or high-risk urologic cancers. It helps doctors learn more about how these cancers are treated in real life.
This Phase 1/2 study tests investigational cancer treatment(s) in people with locally advanced or metastatic urothelial cancer that has not responded to PD-1/PD-L1 immunotherapy. It may help by trying a new approach after prior checkpoint treatment has stopped working or the cancer returns.
This study looks at how well different treatments work for older adults with bladder cancer that has spread and who cannot take cisplatin. It also checks if geriatric assessments help guide care.
This trial tests a new drug, PF-08634404, either by itself or together with another drug called enfortumab vedotin, for people with advanced bladder cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, given before surgery for upper tract urothelial cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes for patients who are candidates for surgery.
This trial is for people with upper tract urothelial cancer who have already had surgery and chemotherapy (cisplatin-based). It tests whether continuing with a drug called avelumab (an immunotherapy) can help prevent the cancer from coming back.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.